DB05474ExperimentalSmall molecule
T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. The formulation is administered orally and has anti-inflammatory... The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
- Mechanism
- Curator reviewed
T487 binds selectively and potently to CXCR3.
- Primary indication
- Investigated for use/treatment in inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of T487, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account